Your browser doesn't support javascript.
loading
Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications.
Fuchs, Kornelius; Rummler, Silke; Ries, Wolfgang; Helmschrott, Matthias; Selbach, Jochen; Ernst, Friedlinde; Morath, Christian; Gauly, Adelheid; Atiye, Saynab; Stauss-Grabo, Manuela; Giefer, Mareike.
Afiliación
  • Fuchs K; Department of Neurology, University Hospital, Regensburg, Germany.
  • Rummler S; Institute for Transfusion Medicine, University Hospital, Jena, Germany.
  • Ries W; Internal Medicine, Department of Nephrology, Diakonissenkrankenhaus, Flensburg, Germany.
  • Helmschrott M; Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany.
  • Selbach J; Department of Nephrology, Caritas Hospital, Bad Mergentheim, Germany.
  • Ernst F; Center for Internal Medicine and Dialysis, Kempten, Germany.
  • Morath C; Department for Dialysis, Nierenzentrum Heidelberg, Heidelberg, Germany.
  • Gauly A; Fresenius Medical Care, Global Medical Office, Bad Homburg, Germany.
  • Atiye S; Fresenius Medical Care, Global Medical Office, Bad Homburg, Germany.
  • Stauss-Grabo M; Fresenius Medical Care, Global Medical Office, Bad Homburg, Germany.
  • Giefer M; Fresenius Medical Care, Global Medical Office, Bad Homburg, Germany.
Ther Apher Dial ; 26(1): 229-241, 2022 Feb.
Article en En | MEDLINE | ID: mdl-33914397
Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorption were the aim of this study. This prospective, noninterventional, multicentre cohort study included patients treated with immunoadsorption (Immunosorba or GLOBAFFIN adsorbers) for any indication. Clinical effectiveness was assessed after termination of the patient's individual treatment schedule. Eighty-one patients were included, 69 were treated with Immunosorba, 11 with GLOBAFFIN, one patient with both adsorbers. A majority of patients was treated for neurological indications, dilated cardiomyopathy, and before or after kidney or heart transplantation. Mean IgG reduction from pre- to post-treatment was 69.9% ± 11.5% for Immunosorba and 74.1% ± 5.0% for GLOBAFFIN, respectively. The overall IgG reduction over a complete treatment block was 68%-93% with Immunosorba and 62%-90% with GLOBAFFIN depending on the duration of the overall treatment. After termination of the immunoadsorption therapy, an improvement of clinical status was observed in 63.0%, stabilization of symptoms in 29.6%, and a deterioration in 4.9% of patients. Changes in fibrinogen, thrombocytes, and albumin were mostly classified as noncritical. Overall, the treatments were well tolerated. Immunoadsorption in routine clinical practice with both GLOBAFFIN and Immunosorba has been safely performed, was well tolerated by patients, and effective in lowering immunoglobulins with an improvement or maintenance of clinical status, thus represents an additional therapeutic option for therapy refractory immune disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidados Posoperatorios / Enfermedades Autoinmunes / Cuidados Preoperatorios / Cardiomiopatía Dilatada / Técnicas de Inmunoadsorción / Enfermedades del Sistema Nervioso Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Ther Apher Dial Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidados Posoperatorios / Enfermedades Autoinmunes / Cuidados Preoperatorios / Cardiomiopatía Dilatada / Técnicas de Inmunoadsorción / Enfermedades del Sistema Nervioso Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Ther Apher Dial Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Australia